Agilent Technologies Inc. (NYSE: A) shares lost ground Wednesday, after it announced the latest expansion of its Altura HPLC column portfolio with the introduction of Altura size exclusion chromatography (SEC) and Altura PLRP-S columns, designed to support critical analytical workflows in biopharmaceutical development and production.
The new SEC and PLRP-S columns – according to this morning’s news release, support critical analytical workflows across a range of biotherapeutic modalities, including peptides, proteins, oligonucleotides, and conjugated therapeutics.
Applications such as aggregate characterization, molecular weight confirmation and size distribution analysis remain essential for evaluating product quality, stability and performance, while drug-to-antibody ratio determination is critical for characterizing antibody-drug conjugates and other conjugated therapeutics as drug modalities continue to increase in complexity.
“Customer reception of the first wave of Altura columns has been overwhelmingly positive, highlighting strong demand for high-performance inert column solutions," said David Edwards, vice president and general manager of Agilent's Chemistries and Supplies Division. "By extending the Altura HPLC columns with Ultra Inert technology to SEC and PLRP-S columns, we are expanding access to inert separation technologies that help scientists achieve more reliable, accurate and reproducible results across critical biopharma analytical workflows."
A shares dropped $2.27, or 1.7%, to $128.87
